Vaccine

Details Vaccine Vaccine

1996-11-25

2000-01-11

Minnifield, Nita

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4242261, 4241841, 4242781, 4241891, 4242031, 4242011, 4242171, 424450, 4242021, A61K 3929, A61K 4500, A61K 3913, A61K 39295

Patent

active

060132647

ABSTRACT:
Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37.degree. C. and is highly immunogenic, for example when the vaccine is administered to infants. The compositions typically comprise HBsAg adsorbed to aluminium phosphate and other antigens, especially those suitable for use in a paediatric vaccine, adsorbed to aluminium phosphate or aluminium hydroxide. Methods for preparing the vaccines and the use of aluminium phosphate to stabilise HBsAg in a multivalent vaccine formulation are also described.

REFERENCES:
patent: 5151023 (1992-09-01), Kuzuhara et al.
patent: 5776468 (1998-07-01), Hauser et al.
Research Disclosure (1991) Sep., 32975 -Polyvalent Antigen Vaccine for Human Use.
Sigma Catalogue (1990) -pp. 147-148.
Sigma Catalogue (1998) -pp. 89-90.
Brummelhuis H G J et al (1981) --Hepatitis B Vaccine -INSERM Symposium No 18 -pp. 51-56.
Lafeber-Schut LJ Th (1981) --Hepatitis B Vaccine -INSERM Symposium No 18 -pp. 105-113.
Coutinho R A et al. (1983) --Develop. Biol. Standard 54:287-292.
Mazert M-C et al (1983) --Develop. Biol. Standard 54:53-62.
Coursaget P et al (1986) --Develop. Biol. Standard 65:169-175.
Coursaget P et al (1986) --Infection and Immunity 51:784-787.
Yvonnet B et al (1986) --Develop. Biol. Standard 65:205-207.
Van Damme P et al (1994) --Viral Hepatitis & Liver Disease -pp. 514-516.
Plotkin S A & Mortimer E A (Eds) (1988) --Vaccines W B Saunders Company -p. 55.
Physicias Desk Reference (1994) --pp. 1149-1151.
Chiron, et al., "Simultaneous Administration of Hepatitis B and Diphtheria/Tetanus/Polio Vaccines", (1984), Lancet, 1:623-624.
F. Andre, et al., "Global Perspectives on Hepatitis", (1983), Perspectives, vol. 4, No. 1, pp. 1-8.
"Polyvalent antigen vaccine for human use", (1991), Research Disclosure, 329.
Coursaget, et al., "Simultaneous Administration of Diphtheria-Tetanus-Pertussis-Polio and Hepatitis B Vaccines in a Simplified Immunization Program: Immune Response to Diphtheria Toxoid, Tetanus Toxoid, Pertussis, and Hepatitis B Surface Antigen" (1986), Infection and Immunity, vol. 51, No. 3, pp. 784-787.
Murphy, et al., "Evaluation of the Pertussis Components of Diphtheria-Tetanus-Pertussis Vaccine", (1983), Pediatrics, vol. 71, No. 2, pp. 200-205.
Giammanco, et al., "Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy", (1991), Vaccine, 9:747-750.
Goto, et al., "Accumulation of Ascites and Increase in Skin Vascular Permeability Observed by Injection of Adsorbed Diphtheria-Purified Pertussis-Tetanus Combined Vaccine in Guinea Pigs", (1991), Microbiol. Immunol., vol. 35, (12), pp. 1143-1148.
Coursaget, et al., "Simultaneous Administration of Diphtheria-Tetanus-Pertussis-Polio Vaccine and Hepatitis B Vaccine in a Simplified Immunization Programme" (1985), Develop. biol. Standard., vol. 65, pp. 169-175.
N. Letvin, "Vaccines Against Human Immunodeficiency Virus --Progress and Prospects", (1993), The New England Journal of Medicine, 329(19):1400-1405.
Polyvalent Antigen Vaccine for Human Use Research Disclosure 329, 1991.

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1459939